EA200200122A1 - Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции - Google Patents

Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции

Info

Publication number
EA200200122A1
EA200200122A1 EA200200122A EA200200122A EA200200122A1 EA 200200122 A1 EA200200122 A1 EA 200200122A1 EA 200200122 A EA200200122 A EA 200200122A EA 200200122 A EA200200122 A EA 200200122A EA 200200122 A1 EA200200122 A1 EA 200200122A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell
compounds
formula
pharmaceutical compositions
interaction
Prior art date
Application number
EA200200122A
Other languages
English (en)
Other versions
EA004369B1 (ru
Inventor
Ануширван Пейман
Карл-Хайнц Шойнеманн
Томас Р. Гейдек
Жан-Франсуа Гурве
Жан-Мари Рюксер
Original Assignee
Авентис Фарма Дойчланд Гмбх
Генентек Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх, Генентек Инк. filed Critical Авентис Фарма Дойчланд Гмбх
Publication of EA200200122A1 publication Critical patent/EA200200122A1/ru
Publication of EA004369B1 publication Critical patent/EA004369B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)в которой В, G, X, Y, Z, r, s и t имеют значения, обозначенные в формуле изобретения, к их физиологически приемлемым солям и их пролекарствам. Соединения формулы (I) представляют собой ценные фармакологически активные соединения. Они являются антагонистами рецептора витронектина и ингибиторами клеточной адгезии и применимы для лечения и профилактики заболеваний, основанных на взаимодействии между рецепторами витронектина и их лигандами в процессах взаимодействия клетка-клетка или клетка-матрикс, или которые могут быть предотвращены, облегчены или излечены воздействием на такие взаимодействия. Например, они могут использоваться для ингибирования резорбции кости остеокластами и, таким образом, для лечения и предотвращения остеопороза или для ингибирования нежелательного сосудообразования или пролиферации клеток гладкой мускулатуры сосудов. Кроме того, изобретение относится к способам получения соединений формулы (I), их применению, в частности, в качестве активных компонентов в фармацевтических препаратах и фармацевтических композициях их содержащих.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200122A 1999-07-02 2000-06-26 Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции EA004369B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99112636A EP1065207A1 (en) 1999-07-02 1999-07-02 Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
PCT/EP2000/005920 WO2001002398A1 (en) 1999-07-02 2000-06-26 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them

Publications (2)

Publication Number Publication Date
EA200200122A1 true EA200200122A1 (ru) 2002-06-27
EA004369B1 EA004369B1 (ru) 2004-04-29

Family

ID=8238482

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200122A EA004369B1 (ru) 1999-07-02 2000-06-26 Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции

Country Status (33)

Country Link
US (2) US6743800B1 (ru)
EP (2) EP1065207A1 (ru)
JP (1) JP2003503496A (ru)
KR (1) KR20020015996A (ru)
CN (1) CN1160356C (ru)
AR (1) AR024622A1 (ru)
AT (1) ATE305471T1 (ru)
AU (1) AU775386B2 (ru)
BG (1) BG106257A (ru)
BR (1) BR0012129A (ru)
CA (1) CA2376668C (ru)
CZ (1) CZ20014605A3 (ru)
DE (2) DE60022890T4 (ru)
DK (1) DK1210348T3 (ru)
EA (1) EA004369B1 (ru)
EE (1) EE200100711A (ru)
ES (1) ES2250157T3 (ru)
HK (1) HK1050003B (ru)
HR (1) HRP20010946A2 (ru)
HU (1) HUP0203539A3 (ru)
IL (1) IL147248A0 (ru)
MX (1) MXPA01013435A (ru)
MY (1) MY133246A (ru)
NO (1) NO20016404L (ru)
NZ (1) NZ516058A (ru)
PL (1) PL352280A1 (ru)
SK (1) SK19132001A3 (ru)
TR (1) TR200103856T2 (ru)
TW (1) TW593319B (ru)
UA (1) UA73133C2 (ru)
WO (1) WO2001002398A1 (ru)
YU (1) YU92201A (ru)
ZA (1) ZA200200016B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
JP4866610B2 (ja) * 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110237605A1 (en) 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP4249471A3 (en) 2013-09-24 2023-10-18 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
AU2022388555A1 (en) 2021-11-09 2024-05-02 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741796A (en) * 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
WO1998008940A1 (en) 1996-08-26 1998-03-05 Novo Nordisk A/S A novel endoglucanase
EP0934305A4 (en) * 1996-08-29 2001-04-11 Merck & Co Inc INTEGRINE ANTAGONISTS
AU717283B2 (en) * 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
AU729869B2 (en) * 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
WO1999037621A1 (en) * 1998-01-23 1999-07-29 Aventis Pharma Deutschland Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
JP2005526709A (ja) * 2002-01-10 2005-09-08 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換ベンゾイミダゾールアナログ
JP2008047614A (ja) 2006-08-11 2008-02-28 Showa Shell Sekiyu Kk 吸着材を利用した改良型太陽電池モジュール

Also Published As

Publication number Publication date
JP2003503496A (ja) 2003-01-28
NO20016404D0 (no) 2001-12-28
NO20016404L (no) 2002-03-01
US20040198718A1 (en) 2004-10-07
DK1210348T3 (da) 2006-01-16
BR0012129A (pt) 2002-05-07
SK19132001A3 (sk) 2002-07-02
MXPA01013435A (es) 2002-07-22
CA2376668C (en) 2007-01-02
AU775386B2 (en) 2004-07-29
CN1372559A (zh) 2002-10-02
UA73133C2 (en) 2005-06-15
EP1065207A1 (en) 2001-01-03
TW593319B (en) 2004-06-21
CA2376668A1 (en) 2001-01-11
ZA200200016B (en) 2003-01-02
ATE305471T1 (de) 2005-10-15
DE60022890D1 (de) 2006-02-09
HUP0203539A3 (en) 2005-01-28
BG106257A (bg) 2002-10-31
MY133246A (en) 2007-10-31
EP1210348A1 (en) 2002-06-05
US6743800B1 (en) 2004-06-01
DE60022890T2 (de) 2006-06-29
ES2250157T3 (es) 2006-04-16
EP1210348B1 (en) 2005-09-28
NZ516058A (en) 2003-01-31
EP1210348B9 (en) 2006-04-26
AU5978700A (en) 2001-01-22
IL147248A0 (en) 2002-08-14
HUP0203539A2 (hu) 2003-02-28
EE200100711A (et) 2003-04-15
HRP20010946A2 (en) 2003-02-28
DE60022890T4 (de) 2007-03-29
PL352280A1 (en) 2003-08-11
HK1050003A1 (en) 2003-06-06
YU92201A (sh) 2004-07-15
HK1050003B (zh) 2005-04-29
WO2001002398A1 (en) 2001-01-11
CN1160356C (zh) 2004-08-04
EA004369B1 (ru) 2004-04-29
CZ20014605A3 (cs) 2002-06-12
KR20020015996A (ko) 2002-03-02
TR200103856T2 (tr) 2002-06-21
AR024622A1 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ATE460413T1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
YU47200A (sh) Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
EA200200122A1 (ru) Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
ATE444965T1 (de) Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
ATE365155T1 (de) 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten
ATE360018T1 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
ATE432934T1 (de) Neue guanidino derivate als zelladhäsionhemmer
HK1066166A1 (en) Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
RU2001107024A (ru) Новые производные карбоновой кислоты, имеющие боковые кетоцепи, их получение и применение в качестве антагонистов рецепторов эндотелина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU